Sonoma Pharmaceuticals, Inc. (SNOA:NASDAQ) closed at $1.14 on November 3, 2026, up 3.64% on the day. The stock trades 71.1% below its 52-week high of $3.95 and 34.1% above its 52-week low of $0.850. Over the past year, it lost 70.9%. Sonoma Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 3, 2025, SNOA closed higher on 98 days (39%). Its best day was April 20, 2026 (+15.22%) and its worst was April 24, 2026 (-36.67%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 1 time.
Sonoma Pharmaceuticals, Inc. designs, produces, and markets prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue, skincare, and animal healthcare markets in the United States, Latin America, Europe, and rest of the world. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of pathogens that cause disease, including viruses, fungi, spores, and bacteria, such as antibiotic-resistant strains. The company's Microcyn has received fourteen 510(k) clearances for use as a medical device in tissue care management consisting of acute and chronic wounds, and in dermatology applications. It also provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Sonoma Pharmaceuticals, Inc. sells its products directly to end users and distributors, and through contract sales force and business partners to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists for the treatment of various skin afflictions. The company was formerly known as Ocul...
Find more stocks like SNOA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.